[HTML][HTML] Remission of renal disease: recounting the challenge, acquiring the goal
BM Brenner - The Journal of clinical investigation, 2002 - Am Soc Clin Investig
BM Brenner
The Journal of clinical investigation, 2002•Am Soc Clin InvestigNonstandard abbreviations used: end-stage renal disease (ESRD); angiotensin-converting
enzyme inhibitor (ACEI); angiotensin receptor blocker (ARB); renin-angiotensin system
(RAS); Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT); Reduction of Endpoints in
NIDDM [non–insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist
Losartan (RENAAL); Ramipril Efficacy in Nephropathy (REIN); Heart Outcomes Prevention
Evaluation (HOPE).
enzyme inhibitor (ACEI); angiotensin receptor blocker (ARB); renin-angiotensin system
(RAS); Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT); Reduction of Endpoints in
NIDDM [non–insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist
Losartan (RENAAL); Ramipril Efficacy in Nephropathy (REIN); Heart Outcomes Prevention
Evaluation (HOPE).
Nonstandard abbreviations used: end-stage renal disease (ESRD); angiotensin-converting enzyme inhibitor (ACEI); angiotensin receptor blocker (ARB); renin-angiotensin system (RAS); Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT); Reduction of Endpoints in NIDDM [non–insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL); Ramipril Efficacy in Nephropathy (REIN); Heart Outcomes Prevention Evaluation (HOPE).
The Journal of Clinical Investigation